Cytokinetics (CYTK)

Cytokinetics (CYTK) Stock Price & Analysis


CYTK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$32.96 - $55.80
Previous Close$37.36
Average Volume (3M)994.45K
Market Cap
Enterprise Value$3.11B
Total Cash (Recent Filing)$663.96M
Total Debt (Recent Filing)$203.71M
Price to Earnings (P/E)-8.2
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding95,640,600
10 Day Avg. Volume652,222
30 Day Avg. Volume994,450
Standard Deviation0.16
Financial Highlights & Ratios
Price to Book (P/B)-15.68
Price to Sales (P/S)774.58
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue31.75
Enterprise Value/Gross Profit32.91
Enterprise Value/Ebitda-8.06
Price Target Upside58.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $32.96 and its highest was $55.80 in the past 12 months.
    What is Cytokinetics’s market cap?
    Currently, no data Available
    When is Cytokinetics’s upcoming earnings report date?
    Cytokinetics’s upcoming earnings report date is Aug 10, 2023 which is in 72 days.
      How were Cytokinetics’s earnings last quarter?
      Cytokinetics released its earnings results on May 04, 2023. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.203 by -$0.177.
        Is Cytokinetics overvalued?
        According to Wall Street analysts Cytokinetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cytokinetics pay dividends?
          Cytokinetics does not currently pay dividends.
          What is Cytokinetics’s EPS estimate?
          Cytokinetics’s EPS estimate is -$1.14.
            How many shares outstanding does Cytokinetics have?
            Cytokinetics has 95,640,600 shares outstanding.
              What happened to Cytokinetics’s price movement after its last earnings report?
              Cytokinetics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.203. Following the earnings report the stock price went up 0.382%.
                Which hedge fund is a major shareholder of Cytokinetics?
                Among the largest hedge funds holding Cytokinetics’s share is Farallon Capital Management, L.L.C.. It holds Cytokinetics’s shares valued at 33M.


                  Cytokinetics Stock Smart Score

                  The Cytokinetics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.


                  Top 5 ETFs holding CYTK

                  Market Value
                  Smart Score
                  Vanguard Health Care ETF
                  iShares Core S&P Total U.S. Stock Market ETF
                  Schwab U.S. Broad Market ETF
                  Fidelity MSCI Health Care Index ETF
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Up to five ETFs with an Outperform Smart Score that hold CYTK. The ETFs are listed according to market value of CYTK within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Cerevel Therapeutics Holdings
                  Denali Therapeutics
                  Intellia Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis